A detailed history of State Street Corp transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 469,601 shares of TRDA stock, worth $8.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
469,601
Previous 445,216 5.48%
Holding current value
$8.42 Million
Previous $6.34 Million 18.35%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.65 - $17.86 $332,855 - $435,516
24,385 Added 5.48%
469,601 $7.51 Million
Q2 2024

Aug 14, 2024

BUY
$11.85 - $16.45 $116,438 - $161,637
9,826 Added 2.26%
445,216 $6.34 Million
Q1 2024

May 15, 2024

BUY
$11.58 - $17.0 $87,521 - $128,486
7,558 Added 1.77%
435,390 $6.17 Million
Q4 2023

Feb 14, 2024

BUY
$11.36 - $16.99 $279,217 - $417,597
24,579 Added 6.1%
427,832 $6.46 Million
Q3 2023

Nov 14, 2023

BUY
$13.61 - $18.01 $164,163 - $217,236
12,062 Added 3.08%
403,253 $6.37 Million
Q2 2023

Aug 14, 2023

BUY
$11.02 - $18.01 $3.6 Million - $5.88 Million
326,614 Added 505.77%
391,191 $5.92 Million
Q1 2023

May 15, 2023

BUY
$9.58 - $16.2 $517 - $874
54 Added 0.08%
64,577 $936,000
Q4 2022

Feb 14, 2023

BUY
$13.52 - $22.89 $422,216 - $714,831
31,229 Added 93.8%
64,523 $872,000
Q3 2022

Nov 15, 2022

BUY
$9.65 - $15.76 $29,915 - $48,856
3,100 Added 10.27%
33,294 $525,000
Q2 2022

Aug 15, 2022

SELL
$5.49 - $12.94 $664,290 - $1.57 Million
-121,000 Reduced 80.03%
30,194 $368,000
Q1 2022

May 16, 2022

BUY
$7.99 - $16.93 $559,899 - $1.19 Million
70,075 Added 86.39%
151,194 $1.42 Million
Q4 2021

Feb 14, 2022

BUY
$13.7 - $35.0 $1.11 Million - $2.84 Million
81,119 New
81,119 $1.39 Million

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $562M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.